Absci (NASDAQ:ABSI - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Zacks reports. The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.77 million. Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%.
Absci Stock Performance
Shares of NASDAQ:ABSI traded down $0.03 during mid-day trading on Friday, reaching $3.01. The company had a trading volume of 3,204,118 shares, compared to its average volume of 2,388,526. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. The firm has a market cap of $383.28 million, a price-to-earnings ratio of -3.24 and a beta of 2.09. The company's 50-day moving average price is $3.86 and its 200-day moving average price is $3.66. Absci has a one year low of $2.45 and a one year high of $6.72.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Absci in a research note on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $9.00 target price on shares of Absci in a research note on Wednesday. KeyCorp cut their target price on Absci from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Finally, Guggenheim restated a "buy" rating and issued a $10.00 target price on shares of Absci in a research note on Thursday. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $8.57.
View Our Latest Stock Analysis on ABSI
Absci Company Profile
(
Get Free Report)
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Further Reading
Before you consider Absci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.
While Absci currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
